Dax

• MAINRITSys : Rituximab vs placebo for maintenance in systemic sclerosis – interstitial lung disease Pending
  2025-521331-36-00 10 Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%)
• Study evaluating two treatment strategies for rectal cancer in patients ≥75 years old Pending
  2025-521619-37-00 5 Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to r
• AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) Recruiting
  2025-520466-22-00 5 2026-04-29 Advanced Platinum-resistant Epithelial Ovarian Cancer
• Lessening Organ Dysfunction with VITamin C in septic ARDS Recruiting
  2024-516394-78-00 5 2024-11-05 Patient with sepsis complicated by ARDS
• CPAAARI-Therapeutic efficacy comparison of a six-month treatment by itraconazole and nebulised Ambisome® versus treatment by itraconazole al … Recruiting
  2024-517004-11-00 5 2024-10-22 Chronic pulmonary aspergillosis
• Apneic oxygenation with high-flow nasal oxygenation after preoxygenation with noninvasive ventilation before intubation in hypoxemic patient … Recruiting
  2024-514949-11-00 5 2026-03-18 Hypoxemic acute respiratory failure
• OBI-WAN : Obinutuzumab for remission induction in patients with relapsing PR3-ANCA granulomatosis with polyangiitis (Wegener’s). Phase 2 pro … Recruiting
  2022-501557-36-00 4 2025-12-19 PR3-ANCA granulomatosis with polyangiitis (Wegener’s)
• Strategies for zoledronic acid post-denosumab discontinuation in postmenopausal osteoporosis Recruiting
  2024-511871-13-00 6 2025-10-02 Postmenopausal osteoporosis
• Combination of baricitinib and anti-TNF in rheumatoid arthritis Recruiting
  2024-511442-39-00 5 2025-02-05 Rheumatoid arthritis (RA)
• PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting
  2024-515297-27-00 5 2024-08-14 colon carcinoma
• UVB: treatment of UVeitis in Behçet’s diseases with biologic Recruiting
  2024-513371-41-00 4 2024-04-25 Severe uveitis of Behçet’s disease
• CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting
  2023-503317-29-00 5 2024-04-12 Metastatic renal cell carcinoma (mRCC)
• Weaning protocol for high-flow nasal oxygen therapy in the ICU - Multicenter randomized controlled trial. HiFloWEAN Recruiting
  2023-504366-36-00 5 2024-02-17 de novo acute respiratory failure
• RIISC Recruiting
  2024-513669-38-00 5 2023-05-17 Stroke, Ischemic, TIA, Cardiac Disease, Atherosclerosis, Myocardial In
• TocilizuMab discontinuAtion in GIant Cell Arteritis Ended recruitment
  2023-505515-21-00 5 2024-04-02 Giant Cell Arteritis
• PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed … Ended recruitment
  2023-505972-32-00 5 2024-02-26 locally advanced anal squamous cell carcinoma
• MEthotrexate versus TOcilizumab for treatment of GIant cell Arteritis: a multicenter, randomized, controlled trial Ended recruitment
  2024-512269-14-00 5 2020-01-27 GIant cell Arteritis
• Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) Ended recruitment
  2023-507889-89-00 5 2016-02-19 Respiratory tract infection
• Salvage Therapy for Patients with Inadequate Response to Standard of Care Therapy in Granulomatosis with Polyangiitis Halted
  2024-516687-28-00 5 2025-06-06 Patients with GPA and inadequate response to standard of care therapy
• SCLERITA - Safety and efficacy of itacitinib in adults with systemic sclerosis: a phase II, randomized, controlled trial Ended
  2024-513648-27-00 4 2024-10-25 Patients with newly or active diffuse Systemic sclerosis (SSc) at the
• A Ph2 dose-finding study (MARS-17) to evaluate the efficacy and safety of GSK3858279 in adults with knee osteoarthritis pain. Ended
  2022-502799-22-00 4 2023-11-29 Knee osteoarthritis pain
• Treatment of non severe Hemophagocytosis Lymphohistiocytosis with ITACITINIB a Phase II prospective trial Ended
  2024-513173-44-00 4 2022-05-03 Adults patients having non severe HLH

Showing 1–22 of 22 trials